Xue Cui1,2, Min Peng2, Honglei Chen1,*
Oncologie, Vol.24, No.4, pp. 665-678, 2022, DOI:10.32604/oncologie.2022.023641
- 31 December 2022
Abstract The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought new life to
cancer treatment, and ICIs can effectively treat various tumors. Among the immune anti-cancer therapies, PD-1 is
undoubtedly the hot target after CTLA-4, but due to the ineffectiveness of PD-1 in treating certain tumors,
researchers have shifted their focus to other combination targets, such as LAG-3, TIM3, IDO-1, etc. One of these
promising targets is LAG-3, a target with multiple clinical trials, which has increasingly shown to be an inhibitory
co-receptor that plays a vital role in autoimmunity, cancer immunity, and More >
Login
Register
